Our study underscores the potential clinical relevance of variability in CD5 staining as a prognostic marker for thymic carcinoma, and the need for further investigation of mechanisms by which CD5 expression may impact the survival of patients with thymic carcinoma. This evidence concerns the gene CD5 and thymic carcinoma.